Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia

Abstract

The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the outcome. However, from… (More)
DOI: 10.1186/s13045-016-0294-x

Topics

1 Figure or Table

Cite this paper

@inproceedings{Mahmud2016EpidermalGF, title={Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia}, author={Hasan Mahmud and Steven M. Kornblau and Arja ter Elst and Frank J. G. Scherpen and Yi Qiu and Kevin R. Coombes and Eveline S. J. M. de Bont}, booktitle={Journal of hematology & oncology}, year={2016} }